Skip to main
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio Inc has experienced a positive shift in its financial landscape following a settlement in 2020 which increased royalty rates on Jemperli sales from 4-8% to 8-25%, along with a one-time payment of $60 million. The outcome of ongoing litigation with GSK could lead to further financial benefits, enhancing AnaptysBio's strategic positioning and potential for future collaborations, all while maintaining a sustainable cash flow to support clinical-stage programs. Management's confidence in the company's value amidst legal challenges, coupled with the prospect of additional indications and assets in development, positions AnaptysBio favorably for future growth.

Bears say

AnaptysBio Inc faces significant risks that contribute to a negative outlook on its stock, including potential safety concerns and lower-than-expected efficacy from its clinical programs, particularly for rosnilimab, which is critical for its growth strategy. Increased competition in the therapeutic landscape and regulatory challenges could further hinder its market position and financial performance, especially if sales do not meet estimations for key products like rosnilimab and Jemperli. Additionally, ongoing legal issues related to intellectual property could lead to diminished revenue and increased legal costs, creating further uncertainty around AnaptysBio's financial stability.

AnaptysBio (ANAB) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 9 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $66.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $66.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.